# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst David Hoang maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Neutral and raises the price target from...
Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price tar...
Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $...
Barclays analyst Carter Gould maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target f...
BMO Capital analyst Evan Seigerman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and raises the price...
Oppenheimer analyst Jay Olson maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and raises the price target f...
HC Wainwright & Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price t...
Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Hold.